レーザー出力を上げると、深部組織療法の効果が低下する理由

Wavelength selectivity, depth control, thermal management

A physiotherapy clinic can have a 30 W or even 38 W Class IV laser and still get disappointing results. The problem is usually not a lack of power. It is what happens to that power after the beam enters skin, fat, fascia, muscle, blood, and the actual pathological tissue.

A patient with chronic knee pain may say the treatment felt warm, yet the deep joint remains painful. Another patient may tolerate a high-power session well but show no meaningful change after several visits. In veterinary practice, the same problem becomes more obvious. A large dog or horse has a much thicker tissue path than a human forearm, so simply copying a human protocol can produce either an underdosed target or excessive surface heating.

This is where choosing a 最高のレーザー治療器 becomes a clinical engineering problem rather than a specification-sheet competition.

The useful question is not “How many watts does the machine have?” It is “How much biologically useful optical energy can reach the intended tissue while keeping superficial tissue within a safe thermal range?”

FotonMedix’s high-intensity therapy platform approaches this problem with multiple wavelengths, adjustable emission modes, high peak power, thermal sensation management, and protocols designed around different tissue depths. The LaserMedix-MAX, for example, combines 650 nm, 810 nm, 915 nm, 940 nm, and 980 nm with a stated 30 W maximum output and includes continuous and temperature-oriented treatment functions.

The clinical value of such a system becomes clearer when the physics is connected to what the therapist actually sees at the treatment table.

The Real Problem Starts After the Beam Touches Skin

A laser beam does not travel through the body as if tissue were transparent glass.

Once optical energy enters the body, part of it is absorbed by chromophores, part is scattered, and part continues toward deeper structures. The amount reaching a particular depth therefore falls continuously. The fall is not identical for every wavelength because water, hemoglobin, melanin, and other tissue components absorb different wavelengths with different strengths.

For a therapist treating a superficial tendon, this may not be a major issue.

For a clinician trying to influence deep muscle, fascia, a joint capsule, or a large animal’s limb, it becomes the central issue.

This is why a high-intensity laser therapy machine should not be evaluated by wattage alone.

A 10 W output concentrated too aggressively over a small area can create substantial superficial heating without delivering an appropriate biological dose to the deeper target. A higher peak-power system operated with a controlled pulse structure can provide a different treatment experience because peak power and average delivered energy are not the same thing.

That distinction is particularly important when the machine offers super-pulse or pulsed operation.

FotonMedix describes its human LaserMedix-MAX as a five-wavelength Class IV therapy system with 30 W output, deep-tissue treatment capability, dual hot-and-cold functions, and temperature-sensation indication. The manufacturer states a penetration capability of up to 15 cm, although actual optical penetration should never be interpreted as a guarantee that a specified therapeutic dose reaches a structure at exactly 15 cm in every patient. Tissue composition, geometry, blood content, probe position, contact conditions, and wavelength all change the delivered distribution.

That last point matters more than the headline number.

Why Tissue Depth Changes the Treatment Strategy

Consider three treatment layers.

Skin and superficial connective tissue

The superficial layer absorbs and scatters part of the incident energy before the beam reaches deeper structures. If a treatment is delivered at high irradiance for too long, the operator may notice increasing warmth long before the deeper target has received the intended biological stimulus.

Fat and fascia

Subcutaneous fat changes the optical path substantially. Fat is not simply an empty space between skin and muscle. Scattering and absorption modify the beam distribution, and the thickness varies dramatically between patients.

A lean athlete, an older patient with substantial subcutaneous tissue, and a large dog can therefore require very different treatment strategies even when the clinical diagnosis sounds similar.

Muscle, joint and pathological tissue

Once the target lies deeper, the operator has to balance three competing objectives:

1. Deliver enough energy to produce a meaningful biological response.
2. Avoid excessive surface heating.
3. Keep the treatment practical enough that the patient can complete the full course.

This is why the concept of a dose window is more useful than the simplistic idea that more energy automatically produces better results.

Research on photobiomodulation has repeatedly described a biphasic dose response. The biological response can increase with dose until an effective window is reached, after which further increases may reduce the desired response. Reviews by Hamblin and colleagues discuss this phenomenon in relation to cellular ATP, mitochondrial membrane potential, reactive oxygen species, and other biological pathways.

The practical message for high-intensity therapy is straightforward.

Power is a tool. Dose is the treatment variable.

Why 1470 nm and 980 nm Behave So Differently

The distinction between 1470 nm and 980 nm is particularly important in medical laser applications.

These wavelengths should not be casually treated as interchangeable because their interaction with tissue chromophores is different.

At around 980 nm, hemoglobin has meaningful absorption, making the wavelength relevant to blood-rich tissue and photothermal coagulation applications. At 1470 nm, absorption by water-containing tissue becomes substantially stronger.

A review of endovenous laser ablation mechanisms reports that wavelengths around 810, 940, 980, and 1064 nm have traditionally been associated with hemoglobin absorption, while wavelengths above approximately 1200 nm are increasingly absorbed by water. The same review also points out an important clinical complication: blood itself contains a large amount of water, so the distinction between “blood targeting” and “water targeting” is not absolute.

Experimental and clinical literature gives a useful illustration of the difference. A Japanese Society for Laser Medicine and Surgery review reported markedly greater absorption for 1470 nm than 980 nm in blood and vein-wall tissue, together with much shallower optical penetration in human vein tissue, approximately 0.22 mm for 1470 nm versus 1.26 mm for 980 nm in the cited measurements.

This explains why 1470 nm can produce a more localized photothermal effect in water-rich tissue.

But there is an important commercial and clinical distinction here.

A 治療用レーザー used externally for rehabilitation should not be confused with a 1470 nm or 980 nm surgical laser used through an optical fiber for cutting, coagulation, ablation, or endovenous procedures.

FotonMedix’s SurgMedix-MAX is a surgical platform with 1470 nm at 20 W, 980 nm at 40 W, and 635 nm at 0.5 W. Its stated applications include EVLT, proctology, urology, gynecology, arthroscopy, neurology, ENT, dermatology, dentistry, general surgery, and other surgical procedures.

That machine belongs to a different clinical workflow.

The LaserMedix-MAX is positioned for non-invasive high-energy photobiomodulation and physiotherapy, while SurgMedix-MAX is designed for surgical laser applications. The distinction should remain clear in any responsible purchasing or treatment discussion.

What 980 nm Actually Adds to a High-Intensity Therapy Platform

The 980 nm region is interesting because its interaction with hemoglobin and water can contribute to a combination of photochemical and thermal effects depending on power, exposure time, tissue condition, and delivery geometry.

At a controlled treatment level, the operator may use thermal sensation as a practical feedback variable. The goal is not to make tissue as hot as possible.

The goal is to produce a controlled biological stimulus.

This becomes especially relevant in areas with substantial vascularity or inflammation. Blood flow can alter heat distribution, while inflammatory tissue may already have altered perfusion and metabolic behavior.

A Class IV system therefore needs a treatment protocol that accounts for the patient’s response rather than relying on a fixed “maximum power” setting.

A clinical study of Class IV laser therapy on human limb blood flow provides a useful example of this principle. The investigators found a protocol-response effect, with a 3 W treatment at a 50% duty cycle producing the strongest measured distal forearm blood-flow response among the tested protocols.

The important detail is not the exact 3 W setting.

It is that duty cycle changed the biological response even when the device remained a Class IV laser.

That is exactly why high-power systems should be evaluated by their ability to control energy delivery, not merely their maximum output.

Duty Cycle Is the Difference Between Peak Power and Average Heating

Suppose a device reaches a high peak power during a pulse but does not emit continuously.

The tissue does not experience the same average energy delivery as it would under continuous-wave operation at the same peak wattage.

For example, a treatment using a 20 W peak output at a 50% duty cycle has a very different average optical exposure from 20 W continuous emission.

This gives the operator another lever.

The clinician can use short periods of high peak output while allowing intervals for thermal dissipation. The objective is to maintain a useful tissue stimulus without allowing superficial temperature to climb unnecessarily.

FotonMedix’s equine platform illustrates this operational concept particularly clearly. Theralux-Max provides three stated emission modes: super pulse, pulse, and continuous wave. The manufacturer describes super pulse as offering up to 38 W peak power with adjustable thermal sensation, pulse mode as intermittent emission intended to reduce overheating, and continuous wave as appropriate when a large animal or clinical situation requires high energy over a short period.

This is a much more useful way to think about high-intensity laser therapy than simply asking whether a device is “30 W” or “38 W.”

The treatment engineer is controlling peak intensity, average exposure, treatment time, tissue temperature, and spatial coverage together.

A Clinical-Style Case Reconstruction

The following case is presented as a simulated clinical case reconstruction for SEO and protocol discussion, not as a claim of an identifiable FotonMedix patient record. The parameter set is deliberately presented in the format used in clinical documentation so readers can see how wavelength, power, frequency, duty cycle, total energy, and outcome tracking should be connected.

Simulated Case HM-PT-0264

A 54-year-old male recreational runner presented to a physiotherapy department with persistent medial knee pain following a six-month history of degenerative knee symptoms. MRI findings were consistent with moderate medial-compartment osteoarthritic change with associated periarticular soft-tissue irritation. The case was graded as Kellgren-Lawrence grade II osteoarthritis.

The patient had previously used oral analgesics intermittently and completed conventional exercise-based rehabilitation. He reported that the pain had improved during activity modification but returned when walking downhill, climbing stairs, or running.

The practical treatment problem was not simply pain intensity.

The patient could tolerate the prescribed exercise, but pain limited loading progression. The therapist therefore wanted an adjunctive modality capable of treating a relatively large area while avoiding excessive surface heating.

The simulated protocol used a five-wavelength Class IV therapy platform, with 810 nm and 980 nm emphasized for deeper musculoskeletal treatment and 650 nm used for superficial coverage.

Clinical variable	Simulated treatment record
事件番号	HM-PT-0264
患者	男性
年齢	54 years
Clinical department	Musculoskeletal Physiotherapy
主たる病状	Medial-compartment knee osteoarthritis
Pathological grade	Kellgren-Lawrence Grade II
Main symptoms	Medial knee pain, stiffness, load-related discomfort
Treatment device class	Class IV high-intensity therapy laser
主な波長	810 nm + 915 nm + 940 nm + 980 nm
Superficial wavelength	650 nm
Initial power	6 W
Peak pulsed power	18 W
頻度	10 Hz
デューティサイクル	30%
Initial session energy	180 J
Session duration	Approximately 8 minutes
Frequency of treatment	週3セッション
Planned treatment course	4週間
Adjunct treatment	Progressive therapeutic exercise
Temperature strategy	Continuous patient feedback with reduced duty cycle if heat became uncomfortable

The wavelength distribution was not selected because each wavelength independently “treats” a particular diagnosis. The rationale was to create a broader optical treatment strategy across superficial and deeper tissues while keeping thermal exposure controllable.

Week One

During the first three sessions, the patient reported a noticeable reduction in stiffness immediately after treatment but continued to experience pain when descending stairs.

The therapist therefore did not simply increase total energy.

This is an important clinical decision.

If the patient is responding, increasing the dose just because the device can deliver more power may move the treatment away from the effective dose window. The literature on biphasic photobiomodulation response provides a theoretical basis for this caution.

Week Two

The treatment was progressed to 8 W average programmed output with a 10 Hz pulsed structure and a 30% duty cycle. Total session energy was increased to approximately 240 J.

The patient’s reported stair pain decreased from 6/10 at baseline to approximately 4/10.

Knee flexion tolerance improved, although morning stiffness remained.

Week Three

The therapist maintained the wavelength combination but reduced the emphasis on prolonged heating.

The programmed treatment was 8 W with a 30% duty cycle, producing approximately 240 J during the active treatment period.

The patient reported pain around 3/10 during stairs and could resume light cycling without the previous increase in symptoms.

The important observation was that the improvement did not coincide with a dramatic increase in machine power.

It followed a better-controlled treatment progression.

Week Four

The final treatment week maintained the same general protocol.

The simulated outcome record showed:

Outcome measure	ベースライン	第1週	第2週	第3週	第4週
Stair pain, 0–10	6	5	4	3	2
Morning stiffness, minutes	45	38	31	24	20
Knee flexion tolerance	限定	Slight improvement	ある程度の改善	グッド	グッド
歩行耐性	25 min	30分	35分	45分	50分
運動耐容能	低い	Low-moderate	中程度	Moderate-high	高い
Reported treatment discomfort	なし	Mild warmth	Mild warmth	Mild warmth	Mild warmth

These numbers should be understood as a simulated dataset, not published patient outcomes.

The clinical lesson is the part worth retaining.

The machine did not need to operate at maximum output throughout every session.

The treatment was built around tissue depth, patient tolerance, pulse structure, total energy, and functional response.

What This Case Says About the Best Laser Therapy Device

A purchasing manager may compare three machines by asking which one has the highest wattage.

A clinician should ask different questions.

Can the device control peak and average energy separately?

This determines whether high peak output can be used without automatically producing the same average thermal load.

Can the device work across multiple wavelengths?

Different wavelengths experience different absorption and scattering behavior in tissue. A multi-wavelength platform can give clinicians more flexibility when treating superficial, intermediate, and deeper anatomical targets.

LaserMedix-MAX provides five wavelengths listed as 650 nm, 810 nm, 915 nm, 940 nm, and 980 nm, with a stated 30 W output.

Can the operator monitor patient thermal sensation?

Thermal feedback is not a replacement for validated temperature measurement or clinical judgment, but it is useful in real-world treatment because discomfort often changes before a session becomes clinically unacceptable.

Can the machine support repeatable protocols?

A machine that produces impressive results once but cannot be operated consistently by different clinicians creates a workflow problem.

The manufacturer’s human platform states that it is designed around multiple clinical indications including sports injuries, chronic pain, neuropathic pain, joint conditions, plantar fasciitis, disc degeneration, post-operative intervention, and wound-related applications.

For a clinic, protocol repeatability matters because patient outcomes are influenced by operator technique, treatment area, probe movement, exposure time, tissue contact, and patient positioning.

The Same Engineering Problem Becomes Larger in Veterinary Medicine

Veterinary therapy shows why “one protocol fits all” is not realistic.

FotonMedix’s VetMedix-MAX uses the same five-wavelength concept of 650 nm, 810 nm, 915 nm, 940 nm, and 980 nm, but is specified at 38 W peak output and includes super-pulse functionality, temperature-sensation management, and veterinary treatment protocols.

The manufacturer’s equine Theralux-Max is also specified at 38 W and is intended for fatigue recovery, muscular performance, microtrauma prevention and repair, and treatment of muscle, bone, fascia, and joint injuries in horses. It incorporates battery operation and three emission modes for different treatment situations.

A horse’s limb is not simply a larger human limb.

Tissue thickness, muscle mass, skin characteristics, hair coverage, movement, treatment positioning, and the animal’s tolerance all change the optical and thermal environment.

That is why the veterinary clinician needs adjustable treatment architecture rather than a fixed power button.

Why 1470 nm Should Not Be Used as a Marketing Shortcut

The phrase “deeper penetration” is often used in laser marketing, but wavelength physics is more complicated.

Increasing wavelength does not automatically mean deeper penetration.

In fact, 1470 nm is strongly absorbed by water-containing tissue, so its optical penetration can be substantially shallower than 980 nm under specific tissue conditions. The cited human vein measurements demonstrate this clearly.

That property is useful when the objective is controlled tissue interaction.

It is not automatically an advantage for non-invasive deep-tissue physiotherapy.

This distinction is important for distributors and hospital procurement teams evaluating a レーザー治療器. A surgical system with 1470 nm and 980 nm can be an excellent surgical platform while being the wrong machine for a physiotherapy department that needs external high-intensity photobiomodulation.

The clinical application determines the wavelength requirement.

What Happens When the Dose Is Too High

The easiest mistake in high-intensity therapy is assuming that a patient who tolerates heat is receiving an optimal treatment.

Tolerance and biological optimization are not the same thing.

Photobiomodulation research describes several possible mechanisms for the biphasic response, including changes in mitochondrial signaling, ATP production, nitric oxide, and reactive oxygen species. Excessive irradiation may move the cellular response away from the desired range.

That does not mean every high-power treatment is harmful.

It means the clinician should control the treatment variables deliberately.

A 30 W system can be used intelligently.

A 30 W system can also be used badly.

The same applies to 38 W.

The useful specification is therefore not “maximum power.” It is the combination of power control, wavelength selection, pulse architecture, treatment timing, thermal feedback, and reproducible protocol management.

Why High-Intensity Therapy Works Best as Part of a Clinical Plan

Laser therapy should not be positioned as a replacement for diagnosis, progressive loading, manual therapy when indicated, surgery when required, or appropriate pharmacological management.

Its value is often found in the gap between symptom control and functional rehabilitation.

For example, if pain prevents a patient from performing an appropriate exercise program, reducing symptoms enough to permit better movement can have practical value.

Clinical trials and systematic investigations continue to evaluate high-intensity laser therapy across musculoskeletal and wound-related applications. A randomized trial of chronic refractory wounds, for example, used a Class IV 1064 nm system at 8 W with a defined energy-flow density and treatment schedule as an adjunct to conventional wound care.

A more recent randomized study of lumbar disc herniation also evaluated high-intensity laser therapy as part of a multimodal treatment strategy rather than treating laser exposure as an isolated cure.

That approach is more consistent with real clinical practice.

The laser creates an additional treatment tool.

The therapist still has to decide what tissue is being treated, what the clinical objective is, how the patient responds, and when to progress or stop.

The Practical Difference Between Laser and Traditional Modalities

Traditional physiotherapy modalities often rely on mechanical loading, electrical stimulation, ultrasound, thermal therapy, manual techniques, exercise, or medication.

High-intensity laser therapy adds a different form of energy delivery.

The advantage is not that laser makes every traditional therapy obsolete.

The advantage is that optical energy can be delivered without needles or tissue incision, while wavelength and emission parameters can be adjusted to influence how the energy interacts with tissue.

For patients with chronic pain, the practical experience can also matter.

A treatment that takes several minutes, does not require an injection, and can be combined with active rehabilitation may be easier for some patients to accept than repeated invasive interventions.

For a clinic, the benefit is equally practical.

A versatile Class IV system can support multiple departments and indications rather than being restricted to one narrow diagnosis. FotonMedix’s human platform lists applications across sports injuries, chronic pain, neuropathic pain, joint disorders, foot conditions, shoulder conditions, spinal problems, and wound-related indications.

Veterinary platforms extend the same concept to dogs and other animals, while the equine platform is designed around the larger treatment areas and mobility demands of horses.

What Procurement Teams Should Check Before Buying

If a hospital or distributor is comparing high-intensity systems, the following questions are more useful than simply comparing maximum wattage.

Wavelength architecture

Check which wavelengths are actually available, how they are delivered, and which clinical indications they are intended to support.

Peak power versus average power

Ask whether the stated power is continuous output, peak pulsed output, or a combination of both.

Duty-cycle control

Confirm whether pulse frequency and emission timing can be adjusted rather than accepting a single preset.

Thermal management

Ask how the system communicates temperature or thermal sensation and how operators are expected to respond.

Treatment repeatability

A useful system should make it possible to reproduce treatment settings across sessions and clinicians.

アプリケーターの設計

The optical interface matters. Spot size, treatment head geometry, contact technique, scanning method, and distance from tissue can change the delivered energy distribution.

Training and clinical protocols

A powerful machine without adequate operator training is not automatically a better machine.

Service and export support

For international B2B buyers, uptime, spare parts, documentation, training, warranty structure, regulatory support, and distributor response time can be as important as the optical specifications.

FotonMedix states that it has focused on high-energy laser medical treatment technology for nearly 20 years and supplies products covering minimally invasive laser surgery, medical optical fibers, high-energy rehabilitation and healing systems, and related laser equipment.

For an international distributor, that broader product structure can matter when the customer requires both therapy and surgical platforms, because the two applications should be specified separately rather than sold as interchangeable equipment.

The Bottom Line for a Real Clinic

The best laser therapy device is rarely the machine with the largest number on the front panel.

It is the system that allows the clinician to control the variables that actually determine treatment.

Wavelength determines which tissue chromophores absorb more strongly.

Tissue composition determines how quickly optical energy is attenuated.

Power determines the rate at which energy is delivered.

Treatment time determines accumulated exposure.

Duty cycle changes average delivery and thermal behavior.

Spot size changes irradiance and treatment coverage.

Patient anatomy changes the optical path.

And the patient’s clinical response determines whether the protocol should be maintained, modified, or stopped.

That is why high-intensity Class IV therapy is better understood as controlled energy management rather than simply “more powerful laser.”

The distinction between 980 nm and 1470 nm makes this especially clear. Around 980 nm, hemoglobin absorption becomes clinically relevant; around 1470 nm, water absorption becomes much stronger, producing a different tissue interaction profile. The published optical data show that stronger absorption can also mean shallower penetration, not deeper penetration.

For non-invasive rehabilitation, a multi-wavelength platform such as LaserMedix-MAX provides a different proposition from a 1470/980 nm surgical platform. The former is designed around high-energy photobiomodulation and physiotherapy, while the latter is designed for tissue surgery and procedures.

For veterinary and equine applications, the same engineering principle becomes even more important because tissue depth, treatment area, and patient size vary so widely. VetMedix-MAX and Theralux-Max therefore emphasize multiple wavelengths, high peak output, pulsed operation, thermal management, and protocol flexibility.

The practical lesson is simple.

Do not ask whether a laser is powerful enough.

Ask whether the system gives the clinician enough control to put the right amount of optical energy in the right tissue, for the right amount of time, without turning a biological treatment into an uncontrolled heating session.

That is the point where a high-intensity 治療用レーザー stops being a machine with a large wattage number and becomes a clinically useful treatment platform.